单中心治疗 IIIB-IVB 期上皮性卵巢癌的质量指标与生存结局。
Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution.
机构信息
Department of Obstetrics and Gynecology, Orebro University Hospital, Orebro, Sweden
Department of Surgery, Orebro University Hospital, Orebro, Sweden.
出版信息
In Vivo. 2019 Sep-Oct;33(5):1521-1530. doi: 10.21873/invivo.11632.
Abstract
BACKGROUND/AIM: To investigate the overall survival rate, quality indicators and treatment outcome in FIGO stage IIIB-IVB epithelial ovarian cancer at a University Hospital in Sweden between 2006 and 2015.
MATERIALS AND METHODS
A cohort of 110 patients was followed-up for 3-12 years after cancer diagnosis. Three main groups (primary surgery, neoadjuvant chemotherapy, palliative treatment), and six subgroups were defined according to treatment modality.
RESULTS
The mean age was 65 years. Patients were observed for a mean of 50 months. The total resection frequency was 83%. Significant differences in overall survival at 5 years were observed between the groups varying from 60% to 12%.
CONCLUSION
Patient age, tumor stage and complete tumor removal at surgery were significant, independent prognostic factors of overall survival. Complication rate was a significant adverse prognostic factor in univariate analysis. Data discrepancy was observed between public quality reports and locally obtained data.
摘要
背景/目的：本研究旨在调查瑞典某大学医院 2006 年至 2015 年期间 FIGO 分期为 IIIB-IVB 的上皮性卵巢癌患者的总生存率、质量指标和治疗结果。
材料与方法
对 110 例患者进行了 3-12 年的随访，根据治疗方式将患者分为三组（初次手术、新辅助化疗、姑息治疗）和六个亚组。
结果
患者的平均年龄为 65 岁，平均观察时间为 50 个月。完全切除肿瘤的频率为 83%。5 年总生存率在不同组间存在显著差异，从 60%到 12%不等。
结论
患者年龄、肿瘤分期和手术时完全切除肿瘤是总生存率的显著、独立的预后因素。并发症发生率在单因素分析中是一个显著的不良预后因素。公共质量报告和本地获得的数据之间存在数据差异。
相似文献
1
Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution.单中心治疗 IIIB-IVB 期上皮性卵巢癌的质量指标与生存结局。
In Vivo. 2019 Sep-Oct;33(5):1521-1530. doi: 10.21873/invivo.11632.
2
The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.FIGO 卵巢癌分期 IVA 与 IVB：新辅助化疗的预后价值和预测价值。
Int J Gynecol Cancer. 2018 Mar;28(3):453-458. doi: 10.1097/IGC.0000000000001186.
3
Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery.原发性手术后妇产科联合会（FIGO）IIIb 期-IIIc 期与 IV 期上皮性卵巢癌患者中残余疾病对总生存的影响。
Acta Obstet Gynecol Scand. 2019 Jan;98(1):34-43. doi: 10.1111/aogs.13453. Epub 2018 Oct 26.
4
Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.新辅助化疗可提高晚期上皮性卵巢癌的R0细胞减灭率，但不能改善最终结局。
Ann Surg Oncol. 2017 May;24(5):1330-1335. doi: 10.1245/s10434-016-5704-3. Epub 2016 Dec 19.
5
Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer.特定区域而非整个腹膜癌指数可预测晚期上皮性卵巢癌的完全切除和生存。
Int J Gynecol Cancer. 2018 Feb;28(2):316-322. doi: 10.1097/IGC.0000000000001173.
6
Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.上皮性卵巢癌手术的集中化：一家外围教学医院的生存结果
Eur J Obstet Gynecol Reprod Biol. 2015 Sep;192:72-8. doi: 10.1016/j.ejogrb.2015.06.013. Epub 2015 Jun 22.
7
Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.FIGO 分期 IV 期上皮性卵巢癌患者中预处理血小板计数和 CA125 水平（PLT-CA125）联合评分的预后分层。
J Ovarian Res. 2019 Jul 31;12(1):72. doi: 10.1186/s13048-019-0544-y.
8
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective.20 年随访：上皮性卵巢癌 IV 期患者肿瘤残留的预后意义。
Acta Obstet Gynecol Scand. 2012 Mar;91(3):308-17. doi: 10.1111/j.1600-0412.2011.01316.x. Epub 2012 Jan 9.
9
Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer.妇科肿瘤中心对初始不完全肿瘤细胞减灭术的晚期卵巢癌患者行化疗后即刻再次手术或间隔减瘤术的结果。
Gynecol Oncol. 2012 Jul;126(1):54-7. doi: 10.1016/j.ygyno.2012.03.044. Epub 2012 Apr 1.
10
Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.上皮性卵巢癌国际妇产科联盟（FIGO）分期 IIA-IV 期患者残余肿瘤大小的预后价值：OVCAD 数据分析。
Int J Gynecol Cancer. 2012 Mar;22(3):380-5. doi: 10.1097/IGC.0b013e31823de6ae.
引用本文的文献
1
Case Report: Long-Term Survival of a Patient with Cerebral Metastasized Ovarian Carcinoma Treated with a Personalized Peptide Vaccine and Anti-PD-1 Therapy.病例报告：一名脑转移卵巢癌患者接受个性化肽疫苗和抗PD-1治疗后的长期生存
Vaccines (Basel). 2024 Apr 9;12(4):397. doi: 10.3390/vaccines12040397.
2
Role of microRNAs in glycolysis in gynecological tumors (Review).微小 RNA 在妇科肿瘤糖酵解中的作用（综述）。
Int J Oncol. 2023 May;62(5). doi: 10.3892/ijo.2023.5511. Epub 2023 Apr 13.
3
The impact of omentectomy on cause-specific survival of Stage I-IIIA epithelial ovarian cancer: A PSM-IPTW analysis based on the SEER database.网膜切除术对Ⅰ-ⅢA期上皮性卵巢癌特定病因生存率的影响：基于监测、流行病学和最终结果（SEER）数据库的倾向评分匹配逆概率加权分析
Front Surg. 2022 Dec 29;9:1052788. doi: 10.3389/fsurg.2022.1052788. eCollection 2022.
4
Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands.在晚期卵巢癌细胞减灭术中使用 PlasmaJet 设备作为辅助治疗：荷兰 PlaComOv 研究的随机对照试验结果。
Ann Surg Oncol. 2022 Aug;29(8):4833-4843. doi: 10.1245/s10434-022-11763-2. Epub 2022 May 13.
5
Survival in Advanced-Stage Epithelial Ovarian Cancer Patients with Cardiophrenic Lymphadenopathy Who Underwent Cytoreductive Surgery: A Systematic Review and Meta-Analysis.接受细胞减灭术的晚期上皮性卵巢癌合并心膈淋巴结肿大患者的生存情况：一项系统评价和荟萃分析
Cancers (Basel). 2021 Oct 7;13(19):5017. doi: 10.3390/cancers13195017.
6
Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models.共价微管稳定剂在紫杉烷耐药卵巢癌模型中的疗效。
Molecules. 2021 Jul 3;26(13):4077. doi: 10.3390/molecules26134077.
7
Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study.基于人群的研究：构建并验证用于预测有远处转移的上皮性卵巢癌患者生存结局的列线图。
BMC Cancer. 2021 May 25;21(1):609. doi: 10.1186/s12885-021-07977-4.
8
Small Non-Coding-RNA in Gynecological Malignancies.妇科恶性肿瘤中的小非编码RNA
Cancers (Basel). 2021 Mar 3;13(5):1085. doi: 10.3390/cancers13051085.
本文引用的文献
1
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.随机对照试验在晚期卵巢肿瘤患者中的淋巴结切除术
N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424.
2
Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).上皮性卵巢癌患者在细胞减灭术和腹腔热灌注化疗（HIPEC）后的长期生存。
Int J Hyperthermia. 2018;35(1):652-657. doi: 10.1080/02656736.2018.1518544. Epub 2018 Oct 8.
3
Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.腹腔内热灌注化疗治疗卵巢癌。
N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618.
4
Data quality in the Swedish Quality Register of Gynecologic Cancer - a Swedish Gynecologic Cancer Group (SweGCG) study.瑞典妇科癌症质量登记处的数据质量 - 瑞典妇科癌症小组（SweGCG）的一项研究。
Acta Oncol. 2018 Mar;57(3):346-353. doi: 10.1080/0284186X.2017.1366048. Epub 2017 Aug 22.
5
Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.晚期卵巢癌初次肿瘤细胞减灭术与新辅助化疗后的生存率比较：一项国家癌症数据库研究
Int J Gynecol Cancer. 2017 Oct;27(8):1610-1618. doi: 10.1097/IGC.0000000000001072.
6
Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?新诊断晚期卵巢癌患者的手术治疗：哪些患者、何时进行以及手术范围？
Curr Opin Oncol. 2017 Sep;29(5):351-358. doi: 10.1097/CCO.0000000000000387.
7
Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).基于人群的卵巢、输卵管、腹膜或未指定来源的浆液性癌女性的生存研究-代表瑞典妇科癌症组（SweGCG）。
Gynecol Oncol. 2017 Jan;144(1):167-173. doi: 10.1016/j.ygyno.2016.10.039. Epub 2016 Nov 3.
8
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.新诊断晚期卵巢癌的新辅助化疗：妇科肿瘤学会和美国临床肿瘤学会临床实践指南
Gynecol Oncol. 2016 Oct;143(1):3-15. doi: 10.1016/j.ygyno.2016.05.022. Epub 2016 Aug 8.
9
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.一项III期随机试验（日本临床肿瘤学组研究JCOG0602）中，新辅助化疗后，III/IV期卵巢癌、输卵管癌和腹膜癌的初始肿瘤细胞减灭术与间隔肿瘤细胞减灭术之间治疗侵袭性的比较
Eur J Cancer. 2016 Sep;64:22-31. doi: 10.1016/j.ejca.2016.05.017. Epub 2016 Jun 17.
10
The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis.淋巴结切除术对卵巢癌患者生存及复发的影响：一项系统评价与荟萃分析
Jpn J Clin Oncol. 2016 Aug;46(8):718-26. doi: 10.1093/jjco/hyw068. Epub 2016 Jun 6.
Zotero 插件